Axsome Therapeutics Provides Update on Continued Progress at Annual Stockholders’ Meeting
June 07, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3 trial in MDD for AXS-05...
Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
May 09, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
May 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator ...
Axsome Therapeutics To Report First Quarter 2019 Financial Results On May 9, 2019
April 29, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Thursday, May 9, 2019 at 8:00 AM Eastern Time NEW YORK, April 29, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 14, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Company to host conference call today at 8:00 AM Eastern NEW YORK, March 14, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing...
Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank
March 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
$46 million total raised in recent financings extends cash runway into at least 4Q 2021 Current financial position fully funds all five ongoing clinical trials NEW YORK, March 06, 2019 (GLOBE...
Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine
March 04, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
First patient enrolled in the MOMENTUM study Trial being conducted under FDA Special Protocol Assessment (SPA) Topline results anticipated in 1Q 2020 NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) --...
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
February 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of inadequate response to prior migraine treatments Trial initiation...
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility
January 07, 2019 18:35 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Provides Year End 2018 Clinical Update
December 27, 2018 07:00 ET
|
Axsome Therapeutics, Inc.
FDA clearance of IND received for Phase 2 trial of AXS-12 in narcolepsy Phase 2 results of AXS-05 in major depressive disorder on track for early January 2019 Phase 3 results of AXS-05 in treatment...